论文部分内容阅读
最近,美国临床肿瘤协会和美国癌症研究会就逆转癌症病人对多种抗癌药物产生耐药的问题,宣布下列临床研究结果,他们把已知耐药的癌症病人分成5组,第1,2,4组使用钙通道阻断剂异博定,第3组用异博定加利多卡因,第5组用三氟拉嗪(一种调钙蛋白抑制剂)。结果均获得部分或全部抑瘤反应。他们认为,抗耐药的产生机制是临床上应用抗癌药后,可以诱使癌细胞反常产生大量 P-糖蛋白(一种膜蛋白),它能将进入细胞内的抗癌药物泵出细胞外,从而使抗癌药物不能在细胞内积聚达到杀伤细胞的浓度。从 P-糖蛋白的功能
Recently, the American Society of Clinical Oncology and the American Cancer Society announced the following clinical studies on the reversal of cancer patients’ resistance to multiple anticancer drugs. They classified patients with known resistance to cancer into five groups, 1st and 2nd In group 4, the calcium channel blocker is isomerdine, the third group is isoporidine plus lidocaine, and the fifth group is trifluoperazine (a calcineurin inhibitor). The results were all or part of the tumor response. They believe that the anti-drug resistance mechanism is the clinical application of anti-cancer drugs, it can induce cancer cells abnormally produce a large number of P-glycoprotein (a membrane protein), which can pump out the cells into the cell anti-cancer drugs In addition, anticancer drugs cannot accumulate in cells to reach the concentration of killer cells. Function from P-glycoprotein